Skip to main content
Top
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Research article

Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study

Authors: Christoforos D Giannaki, Giorgos K Sakkas, Christina Karatzaferi, Georgios M Hadjigeorgiou, Eleftherios Lavdas, Theodoros Kyriakides, Yiannis Koutedakis, Ioannis Stefanidis

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Restless Legs Syndrome is very common in hemodialysis patients however there are no comparative studies assessing the effectiveness of a non-pharmacological treatment to a classical treatment on parameters related to syndromes’ severity and quality of life.

Methods

In this randomized, partially double blind, placebo controlled trial, thirty two hemodialysis patients with restless legs syndrome were randomly assigned into three groups: 1) the exercise training group (N = 16), 2) the dopamine agonists group (ropinirole 0.25 mg/d) (N = 8) and 3) the placebo group (N = 8). The intervention programs lasted 6 months. Restless Legs Syndrome severity was assessed using the international severity scale, physical performance by a battery of tests, muscle size and composition by computed tomography, body composition by Dual Energy X Ray Absorptiometry, while depression score, sleep quality, daily sleepiness and quality of life were assessed through questionnaires.

Results

Exercise training and dopamine agonists were effective in reducing syndrome’s symptoms by 46% (P = 0.009) and 54% (P = 0.001) respectively. Within group changes revealed that both approaches significantly improved quality of life (P < 0.05), however, only the dopamine agonists significantly improved sleep quality (P = 0.009). Within group changes showed a tendency for lean body mass improvements with dopamine agonists, this reached statistical significance only with the exercise training (P = 0.014), which also reduced fat infiltration in muscles (P = 0.044) and improved physical performance (P > 0.05) in various tests. Between group changes detect significant improvements with both exercise and dopamine agonists in depression score (P = 0.003), while only the dopamine agonist treatment was able to significantly improve sleep quality, compared to exercise and placebo (P = 0.016).

Conclusions

A 6-month exercise training regime was as effective as a 6-month low dosage dopamine agonist treatment in reducing restless legs syndrome symptoms and improving depression score in uremic patients. Further research is needed in order to show whether a combination treatment could be more beneficial for the amelioration of RLS.

Trial registration

Appendix
Available only for authorised users
Literature
1.
go back to reference Murtagh FE, Addington-Hall J, Higginson IJ: The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007, 14 (1): 82-99. 10.1053/j.ackd.2006.10.001.CrossRefPubMed Murtagh FE, Addington-Hall J, Higginson IJ: The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007, 14 (1): 82-99. 10.1053/j.ackd.2006.10.001.CrossRefPubMed
2.
go back to reference Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, Costa J, Stiasny-Kolster K, Sampaio C: Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord. 2008, 23 (16): 2267-2302. 10.1002/mds.22254.CrossRefPubMed Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, Costa J, Stiasny-Kolster K, Sampaio C: Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord. 2008, 23 (16): 2267-2302. 10.1002/mds.22254.CrossRefPubMed
3.
go back to reference Trenkwalder C, Stiasny K, Pollmacher T, Wetter T, Schwarz J, Kohnen R, Kazenwadel J, Kruger HP, Ramm S, Kunzel M, et al: L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep. 1995, 18 (8): 681-688.PubMed Trenkwalder C, Stiasny K, Pollmacher T, Wetter T, Schwarz J, Kohnen R, Kazenwadel J, Kruger HP, Ramm S, Kunzel M, et al: L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep. 1995, 18 (8): 681-688.PubMed
4.
go back to reference Pellecchia MT, Vitale C, Sabatini M, Longo K, Amboni M, Bonavita V, Barone P: Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clin Neuropharmacol. 2004, 27 (4): 178-181. 10.1097/01.wnf.0000135480.78529.06.CrossRefPubMed Pellecchia MT, Vitale C, Sabatini M, Longo K, Amboni M, Bonavita V, Barone P: Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clin Neuropharmacol. 2004, 27 (4): 178-181. 10.1097/01.wnf.0000135480.78529.06.CrossRefPubMed
5.
go back to reference Giannaki CD, Sakkas GK, Karatzaferi C, Hadjigeorgiou GM, Lavdas E, Liakopoulos V, Tsianas N, Koukoulis GN, Koutedakis Y, Stefanidis I: Evidence of increased muscle atrophy and impaired quality of life parameters in patients with uremic restless legs syndrome. PLoS One. 2011, 6 (10): e25180-10.1371/journal.pone.0025180.CrossRefPubMedPubMedCentral Giannaki CD, Sakkas GK, Karatzaferi C, Hadjigeorgiou GM, Lavdas E, Liakopoulos V, Tsianas N, Koukoulis GN, Koutedakis Y, Stefanidis I: Evidence of increased muscle atrophy and impaired quality of life parameters in patients with uremic restless legs syndrome. PLoS One. 2011, 6 (10): e25180-10.1371/journal.pone.0025180.CrossRefPubMedPubMedCentral
6.
go back to reference Johansen KL: Anabolic and catabolic mechanisms in end-stage renal disease. Adv Chronic Kidney Dis. 2009, 16 (6): 501-510. 10.1053/j.ackd.2009.07.007.CrossRefPubMed Johansen KL: Anabolic and catabolic mechanisms in end-stage renal disease. Adv Chronic Kidney Dis. 2009, 16 (6): 501-510. 10.1053/j.ackd.2009.07.007.CrossRefPubMed
7.
go back to reference Garcia-Borreguero D, Allen RP, Benes H, Earley C, Happe S, Hogl B, Kohnen R, Paulus W, Rye D, Winkelmann J: Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord. 2007, 22 (S18): S476-S484. 10.1002/mds.21610.CrossRefPubMed Garcia-Borreguero D, Allen RP, Benes H, Earley C, Happe S, Hogl B, Kohnen R, Paulus W, Rye D, Winkelmann J: Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord. 2007, 22 (S18): S476-S484. 10.1002/mds.21610.CrossRefPubMed
8.
go back to reference Lou JS, Kearns G, Benice T, Oken B, Sexton G, Nutt J: Levodopa improves physical fatigue in Parkinson’s disease: a double-blind, placebo-controlled, crossover study. Mov Disord. 2003, 18 (10): 1108-1114. 10.1002/mds.10505.CrossRefPubMed Lou JS, Kearns G, Benice T, Oken B, Sexton G, Nutt J: Levodopa improves physical fatigue in Parkinson’s disease: a double-blind, placebo-controlled, crossover study. Mov Disord. 2003, 18 (10): 1108-1114. 10.1002/mds.10505.CrossRefPubMed
9.
go back to reference Giannaki CD, Sakkas GK, Hadjigeorgiou GM, Karatzaferi C, Patramani G, Lavdas E, Liakopoulos V, Koutedakis Y, Stefanidis I: Non-pharmacological management of periodic limb movements during hemodialysis session in patients with uremic restless legs syndrome. ASAIO J. 2010, 56 (6): 538-542. 10.1097/MAT.0b013e3181f1cc04.CrossRefPubMed Giannaki CD, Sakkas GK, Hadjigeorgiou GM, Karatzaferi C, Patramani G, Lavdas E, Liakopoulos V, Koutedakis Y, Stefanidis I: Non-pharmacological management of periodic limb movements during hemodialysis session in patients with uremic restless legs syndrome. ASAIO J. 2010, 56 (6): 538-542. 10.1097/MAT.0b013e3181f1cc04.CrossRefPubMed
10.
go back to reference Sakkas GK, Hadjigeorgiou GM, Karatzaferi C, Maridaki MD, Giannaki CD, Mertens PR, Rountas C, Vlychou M, Liakopoulos V, Stefanidis I: Intradialytic aerobic exercise training ameliorates symptoms of restless legs syndrome and improves functional capacity in patients on hemodialysis: a pilot study. ASAIO J. 2008, 54 (2): 185-190. 10.1097/MAT.0b013e3181641b07.CrossRefPubMed Sakkas GK, Hadjigeorgiou GM, Karatzaferi C, Maridaki MD, Giannaki CD, Mertens PR, Rountas C, Vlychou M, Liakopoulos V, Stefanidis I: Intradialytic aerobic exercise training ameliorates symptoms of restless legs syndrome and improves functional capacity in patients on hemodialysis: a pilot study. ASAIO J. 2008, 54 (2): 185-190. 10.1097/MAT.0b013e3181641b07.CrossRefPubMed
11.
go back to reference Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J: Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003, 4 (2): 101-119. 10.1016/S1389-9457(03)00010-8.CrossRefPubMed Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J: Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003, 4 (2): 101-119. 10.1016/S1389-9457(03)00010-8.CrossRefPubMed
12.
go back to reference Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C: Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003, 4 (2): 121-132.CrossRefPubMed Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C: Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003, 4 (2): 121-132.CrossRefPubMed
13.
go back to reference Heyward VH: Assessing cardiorespiratory fitness. 1998, Champaign IL, USA: Human Kinetics, 3 Heyward VH: Assessing cardiorespiratory fitness. 1998, Champaign IL, USA: Human Kinetics, 3
14.
go back to reference Mercer TH, Naish PF, Gleeson NP, Wilcock JE, Crawford C: Development of a walking test for the assessment of functional capacity in non-anaemic maintenance dialysis patients. Nephrol Dial Transplant. 1998, 13 (8): 2023-2026. 10.1093/ndt/13.8.2023.CrossRefPubMed Mercer TH, Naish PF, Gleeson NP, Wilcock JE, Crawford C: Development of a walking test for the assessment of functional capacity in non-anaemic maintenance dialysis patients. Nephrol Dial Transplant. 1998, 13 (8): 2023-2026. 10.1093/ndt/13.8.2023.CrossRefPubMed
15.
go back to reference Koufaki P, Mercer T: Assessment and monitoring of physical function for people with CKD. Adv Chronic Kidney Dis. 2009, 16 (6): 410-419. 10.1053/j.ackd.2009.08.010.CrossRefPubMed Koufaki P, Mercer T: Assessment and monitoring of physical function for people with CKD. Adv Chronic Kidney Dis. 2009, 16 (6): 410-419. 10.1053/j.ackd.2009.08.010.CrossRefPubMed
16.
go back to reference Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M: “Buffalo hump” in men with HIV-1 infection. Lancet. 1998, 351 (9106): 867-870. 10.1016/S0140-6736(97)11443-X.CrossRefPubMed Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M: “Buffalo hump” in men with HIV-1 infection. Lancet. 1998, 351 (9106): 867-870. 10.1016/S0140-6736(97)11443-X.CrossRefPubMed
17.
go back to reference Lo JC, Mulligan K, Noor MA, Lee GA, Schwarz JM, Grunfeld C, Schambelan M: The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin Infect Dis. 2004, 39 (5): 732-735. 10.1086/422725.CrossRefPubMedPubMedCentral Lo JC, Mulligan K, Noor MA, Lee GA, Schwarz JM, Grunfeld C, Schambelan M: The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin Infect Dis. 2004, 39 (5): 732-735. 10.1086/422725.CrossRefPubMedPubMedCentral
18.
go back to reference Lee S, Kuk JL, Davidson LE, Hudson R, Kilpatrick K, Graham TE, Ross R: Exercise without weight loss is an effective strategy for obesity reduction in obese individuals with and without Type 2 diabetes. J Appl Physiol. 2005, 99 (3): 1220-1225. 10.1152/japplphysiol.00053.2005.CrossRefPubMed Lee S, Kuk JL, Davidson LE, Hudson R, Kilpatrick K, Graham TE, Ross R: Exercise without weight loss is an effective strategy for obesity reduction in obese individuals with and without Type 2 diabetes. J Appl Physiol. 2005, 99 (3): 1220-1225. 10.1152/japplphysiol.00053.2005.CrossRefPubMed
19.
go back to reference Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH: Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol. 2001, 12 (12): 2797-2806.PubMed Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH: Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol. 2001, 12 (12): 2797-2806.PubMed
20.
go back to reference Zung WW: A self-rating depression scale. Arch Gen Psychiatry. 1965, 12: 63-70. 10.1001/archpsyc.1965.01720310065008.CrossRefPubMed Zung WW: A self-rating depression scale. Arch Gen Psychiatry. 1965, 12: 63-70. 10.1001/archpsyc.1965.01720310065008.CrossRefPubMed
21.
go back to reference Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991, 14 (6): 540-545.PubMed Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991, 14 (6): 540-545.PubMed
22.
go back to reference Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol. 1993, 4 (5): 1205-1213.PubMed Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol. 1993, 4 (5): 1205-1213.PubMed
23.
go back to reference Montagna P, Hornyak M, Ulfberg J, Hong SB, Koester J, Crespi G, Albrecht S: Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med. 2011, 12 (1): 34-40. 10.1016/j.sleep.2010.08.005.CrossRefPubMed Montagna P, Hornyak M, Ulfberg J, Hong SB, Koester J, Crespi G, Albrecht S: Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med. 2011, 12 (1): 34-40. 10.1016/j.sleep.2010.08.005.CrossRefPubMed
24.
go back to reference Aukerman MM, Aukerman D, Bayard M, Tudiver F, Thorp L, Bailey B: Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med. 2006, 19 (5): 487-493. 10.3122/jabfm.19.5.487.CrossRefPubMed Aukerman MM, Aukerman D, Bayard M, Tudiver F, Thorp L, Bailey B: Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med. 2006, 19 (5): 487-493. 10.3122/jabfm.19.5.487.CrossRefPubMed
25.
go back to reference Fulda S, Wetter TC: Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain. 2008, 131 (Pt 4): 902-917.CrossRefPubMed Fulda S, Wetter TC: Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain. 2008, 131 (Pt 4): 902-917.CrossRefPubMed
26.
go back to reference Boecker H, Sprenger T, Spilker ME, Henriksen G, Koppenhoefer M, Wagner KJ, Valet M, Berthele A, Tolle TR: The runner’s high: opioidergic mechanisms in the human brain. Cereb Cortex. 2008, 18 (11): 2523-2531. 10.1093/cercor/bhn013.CrossRefPubMed Boecker H, Sprenger T, Spilker ME, Henriksen G, Koppenhoefer M, Wagner KJ, Valet M, Berthele A, Tolle TR: The runner’s high: opioidergic mechanisms in the human brain. Cereb Cortex. 2008, 18 (11): 2523-2531. 10.1093/cercor/bhn013.CrossRefPubMed
27.
go back to reference Esteves AM, De Mello MT, Pradella-Hallinan M, Tufik S: Effect of acute and chronic physical exercise on patients with periodic leg movements. Med Sci Sports Exerc. 2009, 41 (1): 237-242. 10.1249/MSS.0b013e318183bb22.CrossRefPubMed Esteves AM, De Mello MT, Pradella-Hallinan M, Tufik S: Effect of acute and chronic physical exercise on patients with periodic leg movements. Med Sci Sports Exerc. 2009, 41 (1): 237-242. 10.1249/MSS.0b013e318183bb22.CrossRefPubMed
28.
go back to reference Von Spiczak S, Whone AL, Hammers A, Asselin MC, Turkheimer F, Tings T, Happe S, Paulus W, Trenkwalder C, Brooks DJ: The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study. Brain. 2005, 128 (Pt 4): 906-917.CrossRefPubMed Von Spiczak S, Whone AL, Hammers A, Asselin MC, Turkheimer F, Tings T, Happe S, Paulus W, Trenkwalder C, Brooks DJ: The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study. Brain. 2005, 128 (Pt 4): 906-917.CrossRefPubMed
29.
go back to reference Walters AS, Winkelmann J, Trenkwalder C, Fry JM, Kataria V, Wagner M, Sharma R, Hening W, Li L: Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord. 2001, 16 (6): 1105-1109. 10.1002/mds.1214.CrossRefPubMed Walters AS, Winkelmann J, Trenkwalder C, Fry JM, Kataria V, Wagner M, Sharma R, Hening W, Li L: Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord. 2001, 16 (6): 1105-1109. 10.1002/mds.1214.CrossRefPubMed
30.
go back to reference Walters AS, Ondo WG, Zhu W, Le W: Does the endogenous opiate system play a role in the Restless Legs Syndrome? A pilot post-mortem study. J Neurol Sci. 2009, 279 (1–2): 62-65.CrossRefPubMed Walters AS, Ondo WG, Zhu W, Le W: Does the endogenous opiate system play a role in the Restless Legs Syndrome? A pilot post-mortem study. J Neurol Sci. 2009, 279 (1–2): 62-65.CrossRefPubMed
31.
go back to reference Johansen KL: Exercise and chronic kidney disease: current recommendations. Sports Med. 2005, 35 (6): 485-499. 10.2165/00007256-200535060-00003.CrossRefPubMed Johansen KL: Exercise and chronic kidney disease: current recommendations. Sports Med. 2005, 35 (6): 485-499. 10.2165/00007256-200535060-00003.CrossRefPubMed
32.
go back to reference Mafra D, Guebre-Egziabher F, Fouque D: Body mass index, muscle and fat in chronic kidney disease: questions about survival. Nephrol Dial Transplant. 2008, 23 (8): 2461-2466. 10.1093/ndt/gfn053.CrossRefPubMed Mafra D, Guebre-Egziabher F, Fouque D: Body mass index, muscle and fat in chronic kidney disease: questions about survival. Nephrol Dial Transplant. 2008, 23 (8): 2461-2466. 10.1093/ndt/gfn053.CrossRefPubMed
33.
go back to reference Sakkas GK, Ball D, Mercer TH, Sargeant AJ, Tolfrey K, Naish PF: Atrophy of non-locomotor muscle in patients with end-stage renal failure. Nephrol Dial Transplant. 2003, 18 (10): 2074-2081. 10.1093/ndt/gfg325.CrossRefPubMed Sakkas GK, Ball D, Mercer TH, Sargeant AJ, Tolfrey K, Naish PF: Atrophy of non-locomotor muscle in patients with end-stage renal failure. Nephrol Dial Transplant. 2003, 18 (10): 2074-2081. 10.1093/ndt/gfg325.CrossRefPubMed
34.
go back to reference Sakkas GK, Sargeant AJ, Mercer TH, Ball D, Koufaki P, Karatzaferi C, Naish PF: Changes in muscle morphology in dialysis patients after 6 months of aerobic exercise training. Nephrol Dial Transplant. 2003, 18 (9): 1854-1861. 10.1093/ndt/gfg237.CrossRefPubMed Sakkas GK, Sargeant AJ, Mercer TH, Ball D, Koufaki P, Karatzaferi C, Naish PF: Changes in muscle morphology in dialysis patients after 6 months of aerobic exercise training. Nephrol Dial Transplant. 2003, 18 (9): 1854-1861. 10.1093/ndt/gfg237.CrossRefPubMed
35.
go back to reference Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T: Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol. 2006, 17 (8): 2307-2314. 10.1681/ASN.2006010034.CrossRefPubMed Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T: Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol. 2006, 17 (8): 2307-2314. 10.1681/ASN.2006010034.CrossRefPubMed
36.
go back to reference Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM: Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers. J Psychopharmacol. 2006, 20 (6): 756-770. 10.1177/0269881106060770.CrossRefPubMed Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM: Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers. J Psychopharmacol. 2006, 20 (6): 756-770. 10.1177/0269881106060770.CrossRefPubMed
37.
go back to reference Sakkas GK, Kent-Braun JA, Doyle JW, Shubert T, Gordon P, Johansen KL: Effect of diabetes mellitus on muscle size and strength in patients receiving dialysis therapy. Am J Kidney Dis. 2006, 47 (5): 862-869. 10.1053/j.ajkd.2006.01.013.CrossRefPubMed Sakkas GK, Kent-Braun JA, Doyle JW, Shubert T, Gordon P, Johansen KL: Effect of diabetes mellitus on muscle size and strength in patients receiving dialysis therapy. Am J Kidney Dis. 2006, 47 (5): 862-869. 10.1053/j.ajkd.2006.01.013.CrossRefPubMed
38.
go back to reference Machann J, Haring H, Schick F, Stumvoll M: Intramyocellular lipids and insulin resistance. Diabetes Obes Metab. 2004, 6 (4): 239-248. 10.1111/j.1462-8902.2004.00339.x.CrossRefPubMed Machann J, Haring H, Schick F, Stumvoll M: Intramyocellular lipids and insulin resistance. Diabetes Obes Metab. 2004, 6 (4): 239-248. 10.1111/j.1462-8902.2004.00339.x.CrossRefPubMed
39.
go back to reference Thamer C, Machann J, Bachmann O, Haap M, Dahl D, Wietek B, Tschritter O, Niess A, Brechtel K, Fritsche A, et al: Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insulin sensitivity. J Clin Endocrinol Metab. 2003, 88 (4): 1785-1791. 10.1210/jc.2002-021674.CrossRefPubMed Thamer C, Machann J, Bachmann O, Haap M, Dahl D, Wietek B, Tschritter O, Niess A, Brechtel K, Fritsche A, et al: Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insulin sensitivity. J Clin Endocrinol Metab. 2003, 88 (4): 1785-1791. 10.1210/jc.2002-021674.CrossRefPubMed
40.
go back to reference Mak RH: Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial. 2000, 13 (1): 4-8.CrossRefPubMed Mak RH: Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial. 2000, 13 (1): 4-8.CrossRefPubMed
41.
go back to reference Sakkas GK, Karatzaferi C, Zintzaras E, Giannaki CD, Liakopoulos V, Lavdas E, Damani E, Liakos N, Fezoulidis I, Koutedakis Y, et al: Liver fat, visceral adiposity, and sleep disturbances contribute to the development of insulin resistance and glucose intolerance in nondiabetic dialysis patients. Am J Physiol Regul Integr Comp Physiol. 2008, 295 (6): R1721-R1729. 10.1152/ajpregu.00935.2007.CrossRefPubMed Sakkas GK, Karatzaferi C, Zintzaras E, Giannaki CD, Liakopoulos V, Lavdas E, Damani E, Liakos N, Fezoulidis I, Koutedakis Y, et al: Liver fat, visceral adiposity, and sleep disturbances contribute to the development of insulin resistance and glucose intolerance in nondiabetic dialysis patients. Am J Physiol Regul Integr Comp Physiol. 2008, 295 (6): R1721-R1729. 10.1152/ajpregu.00935.2007.CrossRefPubMed
42.
go back to reference Weisbord SD, Kimmel PL: Health-related quality of life in the era of erythropoietin. Hemodial Int. 2008, 12 (1): 6-15. 10.1111/j.1542-4758.2008.00233.x.CrossRefPubMed Weisbord SD, Kimmel PL: Health-related quality of life in the era of erythropoietin. Hemodial Int. 2008, 12 (1): 6-15. 10.1111/j.1542-4758.2008.00233.x.CrossRefPubMed
43.
go back to reference Montplaisir J, Karrasch J, Haan J, Volc D: Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord. 2006, 21 (10): 1627-1635. 10.1002/mds.21050.CrossRefPubMed Montplaisir J, Karrasch J, Haan J, Volc D: Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord. 2006, 21 (10): 1627-1635. 10.1002/mds.21050.CrossRefPubMed
44.
go back to reference Kawauchi A, Inoue Y, Hashimoto T, Tachibana N, Shirakawa S, Mizutani Y, Ono T, Miki T: Restless legs syndrome in hemodialysis patients: health-related quality of life and laboratory data analysis. Clin Nephrol. 2006, 66 (6): 440-446.CrossRefPubMed Kawauchi A, Inoue Y, Hashimoto T, Tachibana N, Shirakawa S, Mizutani Y, Ono T, Miki T: Restless legs syndrome in hemodialysis patients: health-related quality of life and laboratory data analysis. Clin Nephrol. 2006, 66 (6): 440-446.CrossRefPubMed
45.
go back to reference Kimmel PL, Peterson RA: Depression in patients with end-stage renal disease treated with dialysis: has the time to treat arrived?. Clin J Am Soc Nephrol. 2006, 1 (3): 349-352. 10.2215/CJN.00890306.CrossRefPubMed Kimmel PL, Peterson RA: Depression in patients with end-stage renal disease treated with dialysis: has the time to treat arrived?. Clin J Am Soc Nephrol. 2006, 1 (3): 349-352. 10.2215/CJN.00890306.CrossRefPubMed
46.
go back to reference Gigli GL, Adorati M, Dolso P, Piani A, Valente M, Brotini S, Budai R: Restless legs syndrome in end-stage renal disease. Sleep Med. 2004, 5 (3): 309-315. 10.1016/j.sleep.2004.01.014.CrossRefPubMed Gigli GL, Adorati M, Dolso P, Piani A, Valente M, Brotini S, Budai R: Restless legs syndrome in end-stage renal disease. Sleep Med. 2004, 5 (3): 309-315. 10.1016/j.sleep.2004.01.014.CrossRefPubMed
Metadata
Title
Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study
Authors
Christoforos D Giannaki
Giorgos K Sakkas
Christina Karatzaferi
Georgios M Hadjigeorgiou
Eleftherios Lavdas
Theodoros Kyriakides
Yiannis Koutedakis
Ioannis Stefanidis
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-194

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.